Under the terms of the agreement, LianBio will receive a one-time payment of $25 million. In addition, LianBio is eligible to receive a sales milestone payment of $5 million. Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.

In July 2023, Nanobiotix granted Janssen a worldwide exclusive license, excepting territories previously licensed to LianBio, for the co-development and commercialization of NBTXR3.

“NBTXR3 has demonstrated the potential to improve treatment outcomes across a number of high need solid tumor indications,” said Konstantin Poukalov, Executive Chairman of the LianBio Board of Directors. “We believe this transaction will build upon the strong foundation LianBio has built for NBTXR3 in Asia.”

“LianBio has served as an important partner in the ongoing pivotal NANORAY-312 clinical trial of NBTXR3 in head and neck squamous cell carcinoma,” said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix. “We look forward to continuing to advance the clinical development of NBTXR3 in Asia and bringing new treatment options to those in need around the globe.”
 

About NBTXR3

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, NBTXR3 could potentially be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Read the original article on GlobeNewswire.